TD Cowen Analyst Maintains Buy Rating for Rallybio.

TD Cowen analyst Ritu Baral has reaffirmed their Buy rating on Rallybio (RLYB) shares, which closed at $0.53 last Friday. Baral has a 5-star rating and an average return of 12.8%. The consensus rating for Rallybio is Hold with a $1.00 average price target. Rallybio has a one-year high of $1.25 and a one-year low of $0.22, with an average volume of 2.9M.

TD Cowen analyst Ritu Baral has reaffirmed their Buy rating on Rallybio (RLYB) shares, which closed at $0.53 last Friday. Baral, who holds a 5-star rating and has an average return of 12.8%, believes that the stock remains undervalued despite recent mixed quarterly results. The consensus rating for Rallybio is Hold, with a $1.00 average price target [1].

In the second quarter of 2025, Rallybio reported a GAAP EPS of -$0.22 and revenue of $212M [3]. While the EPS was negative, the revenue figure was slightly higher than the previous quarter, indicating some growth. The stock's one-year high was $1.25, and its one-year low was $0.22, with an average volume of 2.9M shares traded per day.

Rallybio competes with several other companies in the pharmaceutical sector, including Quince Therapeutics (QNCX), ImmunoPrecise Antibodies (IPA), Immix Biopharma (IMMX), Celularity (CELU), BeyondSpring (BYSI), Elutia (ELUT), Surrozen (SRZN), CervoMed (CRVO), VolitionRx (VNRX), and PMV Pharmaceuticals (PMVP). Among these, Quince Therapeutics has higher earnings but lower revenue than Rallybio, and it is trading at a lower price-to-earnings ratio, making it more affordable [1]. However, Rallybio's potential upside of 1,783.24% suggests that analysts believe the stock is more favorable in the long run [1].

Rallybio's stock price has been relatively stable, with a beta of -1.12, indicating that it is 212% less volatile than the S&P 500. In contrast, Quince Therapeutics has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500 [1]. The media sentiment for Rallybio is more favorable, with an average score of 0.77 compared to Quince Therapeutics' score of 0.76 [1].

Despite the mixed Q2 results, Rallybio's strong institutional ownership, with 90.3% of shares held by institutional investors, suggests that large money managers believe in the stock's long-term growth potential [1]. Additionally, the stock's recent performance, with a one-year high of $1.25 and a one-year low of $0.22, indicates that investors are optimistic about its future prospects.

In conclusion, while Rallybio's Q2 results were mixed, the stock's strong institutional ownership, favorable media sentiment, and analysts' positive outlook suggest that it remains a promising investment. Investors should closely monitor the company's future earnings reports and developments in its pipeline to make informed decisions.

References:
[1] https://www.marketbeat.com/stocks/NASDAQ/RLYB/competitors-and-alternatives/
[2] https://www.marketscreener.com/news/consensus-cloud-beats-q2-adjusted-eps-estimates-raises-fy-guidance-ce7c5edcd98cf227
[3] https://seekingalpha.com/news/4481423-rallybio-gaap-eps-of-0_22-revenue-of-212m